anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Increased inflammatory responses and oxidative stress at the wound site following skin trauma impair healing. Furthermore, skin scarring places fibroblasts under severe mechanical stress and aggravates pathological fibrosis. A novel liposomal composite hydrogel is engineered for wound microenvironment remodeling, incorporating dual-loaded liposomes into gelatin methacrylate to create a nanocomposite hydrogel. Notably, tetrahydrocurcumin (THC) and hepatocyte growth factor (HGF) are encapsulated in the hydrophobic and hydrophilic layers of liposomes, respectively. The composite hydrogel maintains porous nanoarchitecture, demonstrating sustainable THC and HGF release and enhanced mechanical properties and biocompatibility. This system effectively promotes cell proliferation and angiogenesis and attenuates apoptosis. It decreases the expression of the inflammatory factors by inhibiting the high-mobility group box /receptor for advanced glycation end product/NF-κB (HMGB1/RAGE/NF-κB)pathway and increases macrophage polarization from M1 to M2 in vitro, effectively controlling inflammatory responses. It exhibits remarkable antioxidant properties by scavenging excess reactive oxygen species and free radicals. Most importantly, it effectively prevents scar formation by restraining the transforming growth factor beta (TGF-β)/Smads pathway that downregulates associated fibrotic factors. It demonstrates strong therapeutic effects against inflammation and fibrosis in a rat skin wound model with biosafety, advancing the development of innovative hydrogel-based therapeutic delivery strategies for clinical scarless wound therapy.
The survey is a screening project for hypertension, which will enroll subjects at the barbershops. The Metline Township (located at Bizerte Town, in the north of Tunisia) will be the geographical area of population enrollment. Barbershops hairdressers will be trained by a medical staff to measure the blood pressure by an ambulatory device.

All subjects willing to participate in the survey will be asked to measure their blood pressure by after at least 5 minutes rest. Three measures will be performed by the Hairdressers, with an interval of 3 minutes between each measure. The mean of the last two measures will be considered. If the mean blood pressure level exceeds 135/85 mmHg the subject will be sent to a physician of his choice.
The invention provides a traditional Chinese medicine composition for benefiting qi and nourishing blood, and a preparation method and application thereof, which aim to solve the problem of deficiency of both qi and blood of a human body. The raw materials for preparing the traditional Chinese medicine composition comprise the following components in parts by weight: 320 portions of ganoderma lucidum, 280 portions of ginseng, 320 portions of rhizoma polygonati, 250 portions of rhizoma polygonati, 290 portions of angelica sinensis. The traditional Chinese medicine composition for tonifying qi and nourishing blood provided by the invention has the effects of tonifying qi and nourishing blood by matching the lucid ganoderma, the ginseng, the rhizoma polygonati and the angelica, and can be used for the auxiliary treatment of qi-blood deficiency syndromes after radiotherapy and chemotherapy of lung cancer. The symptoms include cough with little phlegm, low and slight cough sound, thin and sticky phlegm or blood streak inclusion, shortness of breath, dyspnea and tachypnea, mental fatigue and hypodynamia, red tongue with thin white or thin yellow coating, and thready, weak or rapid pulse. Can also be used for adjuvant treatment of patients with the above symptoms after radiotherapy and chemotherapy of lung cancer in western medicine. The preparation method of the traditional Chinese medicine composition provided by the invention is simple, and effective components can be retained to the maximum extent, so that the traditional Chinese medicine composition can effectively treat symptoms of deficiency of both qi and blood and the like.
The aim of the study is to analyze the results of injection treatment in patients diagnosed with temporomandibular joint dysfunction manifested by pain and/or limited jaw mobility. The analyzed treatment will consist in the administration of autologous blood products into the cavities of the temporomandibular joints. We intend to conduct a prospective study without a control group. Patients suffering from pain in the temporomandibular joints and/or limited jaw mobility, in whom injection treatment is the treatment of choice, and patients in whom first-line therapies (pharmacotherapy, physiotherapy, splint therapy) did not bring the desired results, and intra-articular injections are a generally accepted continuation of the therapeutic protocol. Qualified patients will be treated with autologous blood products (injectable platelet-rich fibrin). Data from specialist literature support the safety and effectiveness of administering the above-mentioned substance to the cavities of the temporomandibular joints. The use of blood products in the form of intra-articular injections is medically justified both in the case of pain in the temporomandibular joints and/or in clinical conditions with limited jaw mobility. Currently available scientific publications on the comparison of the effectiveness of therapy with the use of various autologous substances are not numerous and do not give a clear answer to the question of what therapeutic protocol (type of substance, dose, number of administrations, joint compartment) is the most effective in the given observation period. This study aims to clarify some of these issues in regard to the above-mentioned blood product, and thus to obtain valuable clinical data that may help clinicians in choosing the appropriate use of intra-articular injections in patients with temporomandibular joint dysfunction.
<P>PROBLEM TO BE SOLVED: To provide a transgenic non-human animal inhibiting TROY signals, to provide a transgenic non-human animal having the accentuated substance penetrability of blood brain barriers, and to provide use thereof.  <P>SOLUTION: This transgenic non-human animal inhibiting TROY signals by the expression of dissolvable TROY. The transgenic non-human animal has the accentuated substance penetrability of blood brain barriers. Thereby, the transgenic non-human animal is useful as the model of a disease accompanying the accentuation of the penetration of the blood brain barriers. By the present invention, disease-treating medicines can be screened. Further, a detecting method for detecting the influence of a material on a central nerve by a model animal having the accentuated material permeability of the blood brain barrier is disclosed.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention provides sweet type white spirits which have the effect of blood activating and sleep improvement. The sweet type white spirits are made through the method that during a traditional jiang-flavor white spirit brewing process, auxiliary materials are added when yeast powder is added, then materials are put into a pit for fermentation, distillation and spirit receiving, the auxiliary materials comprise corn, peas, sweet potatoes, potatoes, kudzu vine roots, lilies, rhizoma smilacis glabrae, hawthorn, medlar, eucommia ulmoides, codonopsis pilosula, Chinese yam, malt and grass roots, and the auxiliary materials are dried, ground into powder and evenly mixed. The sweet type white spirits have the advantages that light medicine fragrance and sweet fragrance are added on white spirit taste, the white spirits are soft when in the mouth, and aftertaste, mellowness and restraining are achieved. On smell fragrance, compared with traditional jiang-flavor white spirits, fragrance is rich and strong, and light sweet fragrance and medicine fragrance are achieved. The spirits brewed with the method have certain healthcare effect, and certain effect is achieved on blood activating and sleep improvement. Sand discharging and sand roughening are directly combined, a step is omitted, and time is saved.
Objective: To explore the clinical characteristics, pathological features, and diagnosis and treatment strategies of nasal chondromesenchymal hamartoma (NCMH) in infants and young children. Methods: A retrospective analysis was conducted on seven cases of NCMH infants and young children admitted to Beijing Children's Hospital, Capital Medical University from April 2015 to January 2022. The cohort included 5 males and 2 females, aged from 6 days to 2 years and 3 months. General information, clinical symptoms, imaging findings, treatment plans, postoperative complications, recurrence and follow-up time were collected, summarized and analyzed. Additionally, immunohistochemical characteristics of the lesion were examined. Results: The clinical symptoms of 7 children included nasal congestion, runny nose, open mouth breathing, snoring during sleep, difficulty feeding, and strabismus. All patients underwent electronic nasopharyngoscopy examination, with 5 cases of tumors located in the right nasal cavity and 2 cases in the left nasal cavity. No case of bilateral nasal cavity disease was found. All 7 patients underwent complete imaging examinations, with 5 patients underwent MRI and CT examinations, 1 patient underwent CT examination only, and 1 patient underwent MRI examination only. The CT results showed that all tumors were broad-based, with uneven density, multiple calcifications and bone remodeling, and some exhibited multiple cystic components. The MRI results showed that the tumor showed low signal on T1 weighted imaging and high or slightly high signal on T2 weighted imaging. All patients were diagnosed through histopathological examination and immunohistochemistry, including 7 cases of Ki-67 and SMA (+), 5 cases of S-100 and Vimentin (+), and all EMA and GFAP were negative. All patients underwent endoscopic resection surgery through the nasal approach, with 3 cases using navigation technology. Five cases of tumors were completely removed, and two cases of tumors were mostly removed. No nasal packing was performed after surgery, and no postoperative nasal, ocular, or intracranial complication occurred in all patients. Follow up assessments conducted 6 to 84 months post-surgery revealed no instances of tumor recurrence in any of the patients. Conclusions: The clinical symptoms of children with NCHM mainly depend on the size and location of the tumor. Nasal endoscopic surgery is the main treatment method. In cases where critical structures like the skull base or orbit are implicated, staged surgical interventions may be warranted. Long-term follow-up is strongly advised to monitor for any potential recurrence or complications.
Surgical resection remains the most important component of standard treatment for oral tongue cancer, but may lead to profound functional impacts not effectively compensated by reconstruction surgery. The volume of tongue resection remains one key factor for the post-treatment deterioration of the functional outcomes and quality of life in large oral tongue cancer. Primary chemoradiotherapy without surgical resection has not been accepted for oral tongue cancer because of the concerns about possible poorer response and sequelae. Breast conservation treatment, by the sequential use of induction chemotherapy (ICT), limited surgical resection and chemoradiotherapy, has become a standard treatment for human breast cancer of various stages. However, similar tongue conservation treatment for advanced oral tongue cancer has not been studied in trials. Based on these data, it will be reasonable, in locally advanced (\> 3 cm) resectable oral tongue cancers, to test whether ICT followed by tongue conservation surgery and postoperative CCRT can safely enhance the possibility of tongue conservation with improved post-treatment functions.
Novel compounds of the Formula I wherein R 1 is H, CH 3 or C 2 H 5 and R 2 is CH 3 or C 2 H 5 , and acid addition salts thereof, are obtained (a) by reacting a reactive ester (e.g. hydrohalic ester or p-toluene sulphonic ester) of an alcoholic of Formula II with an amine of formula R 1 R 2 NH, (b) by dehydrating a compound of Formula IV e.g. by boiling with mineral acid, (c) by methylating or ethylating a compound of Formula I in which R 2 is H, or (d) by hydrolysis of a compound of the Formula I in which R 1 represents a protecting group capable of being split off by hydrolysis, e.g. benzenesulphonyl groups, especially tosyl, p-nitrobenzene sulphonyl, h-bromobenzene sulphonyl, or an acyl group. The compounds may be isolated as free bases or as acid addition salts. 5 - Methylene - 10 - bromomethyl - 5H - dibenzo[a,d]cycloheptene is obtained by bromination of 5-methylene-10-methyl-5H-dibenzo[a,d]- cycloheptene with N-bromosuccinimide. Pharmaceutical compositions useful as anticonvulsants, antiepileptics, tranquilizers, psychosedatives, muscle relaxants and antiparkinson agents, comprise compounds of Formula I in association with a pharmaceutically acceptable carrier in forms suitable for enteral or parenteral administration.
Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
The invention belongs to the technical field of high molecular material polyester synthesis, and particularly relates to a degradable polymer and a preparation method and application thereof. The invention carries out bulk polymerization by taking epsilon-caprolactone monomer and hydroxyl phenylboronic acid as raw materials. The hydroxyl phenylboronic acid is used as an initiator and a catalyst, and the degradable polymer with phenylboronic acid at the alpha-end and hydroxyl at the omega-end is directly obtained without removing the catalyst after reaction. The reaction rate is high, the yield of the obtained product is high, the process flow is short, the operation is simple, the cytotoxicity is avoided, the biological safety of the polycaprolactone can be effectively improved, and the application of the polycaprolactone is wider. According to the invention, the two ends of the polyester-based main chain are respectively connected with the hydroxyphenylboronic acid structure and the hydroxyl structure, so that the water solubility of the degradable polymer formed by the polyester-based main chain is effectively improved, and the hydrophilicity is obviously improved. Meanwhile, a reactive end group functional group is introduced, so that the crystallization performance is reduced, the surface functionality is increased, and the intra-molecular environment is more excellent.
PURPOSE: A composition containing bee venom for preventing and treating acne is provided to ensure antibacterial activity to Propionibacterium acnes and to help regeneration of skin cells. CONSTITUTION: A composition for preventing or treating acne contains bee venom as an active ingredient. The concentration is 0.0001-10%(w/v). A cosmetic composition for preventing or treating acne contains bee venom as an active ingredient. A body cleansing instrument for preventing or treating acne contains bee venom as an active ingredient. The composition is manufactured in a form of liquids, creams, pastes, or solids. The composition additionally contains aqueous ingredient, oil ingredient, surfactant, moisturizer, tackifier, antiseptic and perfume.
Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
LN-144 Generation 3 (Gen 3) therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.
A variety of tools and techniques are disclosed for managing, viewing, publishing, searching, clustering, and otherwise manipulating data streams. Data streams such as RSS data feeds may be searched, aggregated, and filtered into a processed feed. The processed feed, along with rules used to process the feed may be shared in a number of ways. A data feed management system may provide an integrated user interface through which a user may manage feeds, including searching for new feeds, managing and filtering current feeds, modifying a user profile, and sharing feeds and feed configuration data with other users. A server may provide a complementary search engine to locate new feeds and to store and/or index items or posts in known feeds. Together, these technologies may provide a richly-functioned feed management system and greater ease of use for individuals in managing large numbers of feeds and large amounts of data in feeds. Additional functional layers may provide for authentication, security, and privacy, metadata creation and management, and social networking features. Using the management tools and additional functionality, a syndicated data stream system may provide a platform for a wide array of useful consumer and business applications.
Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is \> 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at \> 4 but \< 24 hours if the initial response was positive and there has been subsequent deterioration.
The invention discloses an AI learning-based virtual character chat dialogue system. In the invention, a virtual chat software is designed. Let the platform release the speech which is not in the way at ordinary times, and give a little comfort to oneself. Every user who thinks about relatives can find out the proprietary estuary belonging to the user. The target users are those who want to share their emotions, ideas and memories, and want to stay in contact with the relatives that have elapsed. Such persons may experience significant loss, such as death of the parents, who wish to relieve stress and communicate with their loved ones, and the elapsed parents apply a piece of application software that is very deep and affective, allowing them to recall the deceased friends and share memory together, allowing those who want to speak with the parents but have no opportunity to find a platform. The software adopts the latest technical means to simulate the conversation between people and continuously learn, thus becoming more realistic.
The present invention relates to a novel bifidobacterium bifidum MG731 (Bifidobacterium bifidum MG) strain and a composition for preventing or treating cancer, which comprises the same. Specifically, the bifidobacterium bifidum MG731 strain of the present invention has the effects of inhibiting proliferation of cancer cells, reducing mobility of cancer cells, inhibiting neovascularization, enhancing anticancer immune response, and simultaneously reducing expression of inflammatory factors, thereby having the effect of preventing or treating cancer or inflammatory diseases. Also, the bifidobacterium bifidum MG731 strain of the present invention exhibits more excellent anticancer effects when used in combination with other anticancer agents or immune anticancer agents. The present invention also relates to a novel Lactococcus lactis GEN3033 (Lactococcus LACTIS GEN 3033) strain and a composition for preventing or treating cancer, which contains the same. Specifically, the lactococcus lactis GEN3033 strain of the invention has the direct cancer cell proliferation inhibition and immunity enhancement effects, and has the effect of preventing or treating cancers. Also, the lactococcus lactis GEN3033 strain of the present invention exhibits more excellent anticancer effects when used in combination with other anticancer agents or immunological anticancer agents.
Takotsubo cardiomyopathy (TTC) is a rare condition associated with transient akinesia of apical segments and hyperkinesia of basal segments of the heart. Although several mechanisms have been proposed to cause direct and indirect myocardial damage owing to catecholamine excess, the underlying pathophysiology remains unknown. An 18-year-old female was referred to our otorhinolaryngology outpatient clinic for a septorhinoplasty. Apart from the fear of surgery, the patient had no other health issues. After the administration of local anesthesia (lidocaine and epinephrine mix), tachycardia storms occurred and soon ended with cardiac collapse. Further evaluation revealed TTC. TTC should be considered, especially in cases of treatment-resistant hemodynamic problems after cardiac resuscitation, and nurses can play a crucial role during the preanesthetic period in helping the patient cope with the stress factors related to the upcoming surgery.
Levothyroxine sodium tablets are contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T3 and T4 levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids (see PRECAUTIONS). Levothyroxine sodium is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets. (See DESCRIPTION: Inactive Ingredients.)

WARNING: Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.